Lilly has obtained marketing authorization for tirzepatide from the Italian Medicines Agency (AIFA). The marketing of the innovative drug indicated for the treatment of obesity, overweight in the presence of at least one comorbidity and type 2 diabetes then begins. Tirzepatide is now available on the Italian market on medical prescription. Thanks to its ability to activate both the Gip and Glp-1 receptors – reports a note – in clinical studies, treatment with tirzepatide resulted in a significant weight reduction both in adult patients with obesity and in those who are overweight with at least one comorbidity. related, as well as having demonstrated important results in glycemic control in adults with type 2 diabetes.
Tirzepatide is the first, and to date the only, treatment part of a new therapeutic class that activates both the hormone receptors of Gip (glucose-dependent insulinotropic polypeptide) and those of Glp-1 (glucagon-like peptide-1). By binding both receptors, tirzepatide increases pancreatic insulin secretion, insulin sensitivity and reduces food intake. But what differentiates tirzepatide is the Gip receptor agonism, which acts on weight-related mechanisms: it has beneficial actions at the adipose tissue level, reducing caloric intake and the feeling of nausea.
“Despite the progress made in recent years, obesity remains a very complex condition to deal with for health professionals and systems, with significant cultural and healthcare deficiencies due to its multifactorial nature, its chronic and progressive course, and the many clinical complications associated and, ultimately, to the difficulty in obtaining lasting results in reducing body weight – states Rocco Barazzoni, president of the Italian Obesity Society – Today we are finally entering a new phase in the treatment of obesity, with a new pharmacological paradigm which will allow us not only to provide answers to care needs that have so far been largely unsatisfied, restoring time and quality of life to patients, but also to prevent the numerous associated pathologies in the final stage and reduce their dramatic impact today”.
“Tirzepatide is a new, fundamental chapter in Lilly’s commitment to the metabolic area: a commitment that over almost 100 years, starting from the first commercial insulin in the world, has translated into decisive innovations to move ever further forward the frontier of quality of life for patients – declares Elias Khalil, president and CEO of Lilly Italy hub – Starting from research and know-how in this area, today we broaden the scope of our innovations by making available a molecule that also redefines the treatment of obesity and has the potential to improve the lives of many people living with this chronic, progressive disease which is associated with some of the leading causes of death, including heart disease, cancer, stroke and diabetes.”
The most common side effects – concludes the note – are gastrointestinal, such as nausea and diarrhea. In general, these reactions were mostly mild or moderate in severity and occurred more often during dose escalation and decreased over time. Tirzepatide is currently available in class Cnn in Italy (non-negotiated class C). Lilly is actively engaged in discussions with AIFA to make tirzepatide available to Italian patients covered by the NHS.
#Obesity #diabetes #tirzepatide #arrives #Italy